Case Note & Summary
The dispute arose between shareholders of two pharmaceutical companies regarding the transfer of shareholdings. The petitioners, Dr. Mrs. Renuka Datla and Dr. Vijay Kumar Datla, filed suits in the City Civil Court, Hyderabad, seeking interim injunctions against the transfer of shares by the respondents, Solvay Pharmaceutical B.V. and Shri D. Vasant Kumar. The trial court dismissed the interim injunction application for one suit but granted it for the other two, leading to appeals in the High Court. The High Court dismissed the petitioners' appeal and vacated the injunctions in the other two cases. The petitioners then filed Special Leave Petitions (SLPs) in the Supreme Court. During the proceedings, the parties reached a settlement, which included the valuation of the petitioners' 4.91% shareholding in the companies. The settlement terms required the valuation to be completed within four weeks, and the valuation was conducted by Chartered Accountant Shri Y.H. Malegam, who determined the value to be Rs. 8.24 crores. The petitioners objected to the valuation, arguing that it should include a control premium and the value of certain brands. The court found that the terms of settlement did not provide for a control premium and upheld the valuation methodology used by the valuer. The court directed the respondents to pay interest on the valuation amount for a period of 12 months. Ultimately, the SLPs were disposed of in accordance with the settlement, and the suits were dismissed as withdrawn.
Headnote
A) Companies Law - Share Valuation - Control Premium - Companies Act, 1956, Section 399 - The court addressed whether the valuation of shares should include a control premium based on the petitioners' claim of special rights associated with their shareholding. The court held that the terms of settlement did not expressly require a control premium to be added, thus affirming the valuation as per the agreed terms (Paras 34-35). B) Companies Law - Valuation Methodology - Earnings Based Valuation - Companies Act, 1956, Section 399 - The court examined the appropriateness of the valuation methods used by the valuer, particularly the exclusion of the discounted cash flow method. It was held that the valuer's approach was justified given the discrepancies in projections provided by the parties (Paras 45-46).
Issue of Consideration
Whether the valuation of shares included a control premium and the valuation methods applied were appropriate.
Final Decision
The court dismissed the interim applications and upheld the valuation of Rs. 8.24 crores for the shares without a control premium. It directed the respondents to pay interest at 9% for 12 months on the valuation amount, and the SLPs were disposed of in terms of the settlement.
Law Points
- Valuation of shares
- Interim injunction
- Settlement agreement
- Companies Act
- 1956
- Control premium
- Earnings based valuation
